AUA 2017 - Results from #240

Viewing 241-260 of 344 articles

Phase 3 Randomised Trial of Intravenous Mannitol Versus Placebo During Nephron-Sparing Surgery: Impact on Renal Function Outcomes

AUA 2017: Excised Parenchymal Mass and Devascularized Parenchymal Mass

AUA 2017: Can CT Imaging Predict Stone Impaction

AUA 2017: DNA Repair Defects in Prostate Cancer

AUA 2017: Do Sicker People Have Worse Prostate Cancer-Specific Outcomes After Radical Prostatectomy? Results from SEARCH

AUA 2017: Evaluation of Prebiopsy Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer in Men Aged 75 Years and Older with Elevated PSA

AUA 2017: Combining 4KScore and Magnetic Resonance Imaging (MRI) for Prostate Biopsy Decision Making

AUA 2017: Does baseline serum testosterone influence androgen deprivation therapy outcomes for advanced prostate cancer patients?

AUA 2017: Additive Prognostic Impact of Elevated De Ritis Ratio and Renal Score for Prediction of Survival Outcomes in Renal Cell Carcinoma After Surgical Treatment

AUA 2017: Determinants of Default From Follow-Up Care in a Prostate Cancer Screening Program

AUA 2017: Postoperative Urinary Retention Is An Independent Predictor Of Short-And Long-Term Future Bladder Outlet Procedure In Men

AUA 2017: Urine Based Rapid Molecular Diagnosis of Zika Virus

AUA 2017: Practice patterns across specialties in the treatment of women with recurrent UTIs in an academic healthcare system

AUA 2017: The Whitmore Lecture

AUA 2017: Reflex Testing with Serum, Urine, and Tissue Biomarkers – Which, When and How Valuable?

AUA 2017: Genetic Testing in Inherited Prostate Cancer Risk: Consensus Statement

AUA 2017: Best Prostate Cancer Papers from Past Years

AUA 2017: Incidence of Stress Incontinence Following Posterior Urethroplasty Among Radiation-Induced Posterior Urethral Stenoses

AUA 2017: Quality of life among men after after Rectourethral fistula repair

AUA 2017: High risk non-muscle invasive bladder cancer treated with sequential BCG/electromotive drug administration mitomycin C (EDMA-MMC): 2% disease-specific mortality at 4 years’ follow-up

8
9
10
11
12
13
14
15
16
17